ERBB2 and breast carcinoma: For ER-positive patients, luminal A outperformed luminal B while in ER-negative cancers, the prognosis of basal-like subtype was better than HER2-enriched subtype for Taiwanese breast cancers (Figure 1(b) and 1(c), respectively).